PubMed Health⌕ Search

Biomedical subjects

Iu A Pytel'

Publications and source records attributed to Iu A Pytel'.

At least 127 records · Page 7Linked to original sources
PubMedDate not supplied

[Age-related characteristics of the manifestation of the diabetogenic factor in the blood of animals maintained on natural and atherogenic diets].

The diabetogenic activity was studied in the blood plasma of rats of different age, kept on the natural and atherogenic diet. The relationship between the diabetogenic factor presence and functional condition of the anticoagulating system was investigated. The plasma of rat donors, examined for the presence of diabetogenic factor in their blood, was transfused to normal rat recipients (three transfusions of 1 ml per 200 g body weight daily). The activity of diabetogenic factor was determined according to a hyperglycemia degree in the blood of normal rat recipients. It was found that the blood plasma of old animals, kept on the natural diet, contains heparin-neutralizing diabetogenic factor. In middle-aged animals, kept on the atherogenic diet for a long time, the arising of more active diabetogenic factor in the blood is accelerated. The degree of the diabetogenic effect development in animal donors is directly dependent on their age and the function depression extent of the second anticoagulative system.

Aging↗
PubMedDate not supplied

[Experimental analysis of the pathophysiological significance of the "diabetogenic factor" present in the blood of animals with alloxan diabetes].

Hyperglycemia, induced by the disorder of Langerhans' islet structure and function, and hyperuricemia caused by purine metabolism pathological changes, appeared in the animals with experimental diabetes provoked by a single alloxan injection. As a result, endogenous alloxan-like factor, forming chronic diabetogenic background in the organism, arises and persists in the blood of the animals tested. Under these conditions, heparin exerts preventive and therapeutic effects due to alloxan or endogenous alloxan-like factor binding into complexes devoid of toxic activity.

Alloxan↗
PubMedDate not supplied

[Diabetogenic factor in the blood plasma in diabetes mellitus].

The blood plasma of rats with stable alloxan diabetes, injected three times in appropriate intravenous doses to intact rats, provoked in the rats-recipients hyperglycemia and hyperuricemia, persisted within 14 days. Under the same conditions the blood plasma of patients with diabetes mellitus induced hyperglycemia in the rats-recipients without hyperuricemia development during the same time period. A preliminary intravenous injection of heparin in a dose of 100 E (5 minutes before injecting the plasma of rats with alloxan diabetes or the plasma of patients with diabetes mellitus) completely prevented hyperglycemia and hyperuricemia development in the recipients. Intravenous injections of the blood plasma of healthy animals and humans did not provoke hyperglycemia and hyperuricemia arising in the rats-recipients. It is concluded, that in the blood plasma of animals with alloxan diabetes and in patients with diabetes mellitus the diabetogenic factor is present, being deactivated under heparin effect.

Animals↗
PubMedDate not supplied

[The therapy of chronic nonobstructive pyelonephritis].

Combined therapy for chronic nonobstructive pyelonephritis introduced by the authors includes such components as etiological, pathogenetic, resistance-stimulating. The cure was achieved in 60% of the patients.

Anti-Infective Agents↗
PubMedDate not supplied

[Lymphadenectomy in kidney cancer].

Metastases of renal carcinoma (RC) to lymph nodes were revealed in 121 (18.1%) patients from 667 operated on RC subjects. The frequency of lymph node involvement increases with T: T1--7.5%, T2--10.8%, T3--21.5%, T4--53.3%. In 42 patients the metastases were found only morphologically. In carcinoma of the right kidney the metastases most frequently affected paracaval and interaortocaval lymph nodes, in left kidney carcinoma para-aortal lymph nodes. Preoperative diagnosis of RC metastases to the lymph nodes is not feasible in N1, doubtful in N2 and quite possible in N3. Computed tomography is the most informative procedure as it detects lymphogenic metastases in 82% in N2 and 96% in N3. Overall 5-year survival of RC patients with lymph node metastases was 34.1% (T1N1--80%, T2N2--66.6%, T3N1--41.9%, T3N2--23.5%. All the patients with N3 died within 3 years. The authors think it necessary to perform regional and juxta-regional lymphadenectomy in any surgical intervention for RC in visually unaffected lymph nodes, in N1 and solitary N2. In multiple N2 and in N3 lymphadenectomy is useless.

Adolescent↗
PubMedDate not supplied

[Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia].

The drug proskar (finasteride) belongs to 5 alpha-reductase blockers breaking the steps of prostatic adenoma pathogenesis. Proskar (Merck and Co. Inc., USA) was given to 38 patients with prostatic adenoma stage I and II (residual urine < 50 ml) admitted to urological clinic of the Moscow Medical Academy in 1993-1995. Daily dose was 5 mg. In patients with associated inflammation it was treated prior to proskar administration. To reject carcinoma, patients with elevated levels of prostatic specific antigen (< 4 ng/ml) were subjected to polyfocal biopsy of the gland. In any case, these patients received antiandrogens flutamide or androkur. Subjective response was achieved in 33 of 38 patients (86.8%). Better urination was reported in 29 patients (76.3%). Abdominal and transrectal ultrasonic scanning registered a decrease in the size of the prostate in 25 (65.8%) patients. Proskar was well tolerated, sexual disturbances occurred only in 2 patients. Proskar is effective in therapy of prostatic adenoma stage I. However, its intake must be long and regular, otherwise recurrent clinical symptoms and further growth of prostatic adenoma are possible.

5-alpha Reductase Inhibitors↗